Overview

A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's Disease

Status:
Completed

Trial end date:
2003-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the relative effects of galantamine compared to donepezil (both cholinesteraste inhibitors), on sleep, attention, and gastrointestinal tolerance in patients with Alzheimer's disease.

Phase:

Phase 4

Details

Lead Sponsor:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Collaborator:

Ortho-McNeil Neurologics, Inc.

Treatments:

Donepezil
Galantamine